Multiple Myeloma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Multiple myeloma is characterized by a monoclonal proliferation of plasma cells, resulting in monoclonal antibodies and end-organ damage. This can damage bone marrow, resulting in cytopenia, frail, brittle bones, or renal failure. The accumulation of the monoclonal antibody, Bence–Jones proteins, can precipitate in the urine resulting in kidney damage (usually type 2 renal tubular acidosis) and renal failure, which can be seen in two-thirds of MM cases.
·
An estimated 160,000 cases of Multiple myeloma
were diagnosed globally, accounting for around 1% of all cancer-diagnosed
cases. Approximately 90,000 of those cases were male, and 70,000 were female,
which equals an age-standardized incidence of 2.1/100,000 and 1.4/100,000,
respectively.
·
Approximately 59,000 of those deaths were
male, and 47,000 were female, equalling age-standardized mortality of
1.3/100,000 and 0.9/100,000, respectively.
Thelansis’s “Multiple Myeloma Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Multiple
Myeloma treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Multiple Myeloma across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Multiple Myeloma Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment